| Literature DB >> 32422372 |
Moisés A Calderon1, Susan Waserman2, David I Bernstein3, Pascal Demoly4, Jo Douglass5, Remi Gagnon6, Constance H Katelaris7, Harold Kim8, Harold S Nelson9, Yoshitaka Okamoto10, Kimihiro Okubo11, J Christian Virchow12, Lawrence DuBuske13, Thomas B Casale14, G Walter Canonica15, Hendrik Nolte16.
Abstract
Allergen immunotherapy (AIT) reduces symptoms and medication use associated with allergic rhinitis with or without conjunctivitis and allergic asthma. Although several AIT guidelines exist, there remain unanswered questions about AIT that are relevant to everyday practice. Our objective was to prepare an evidence-based overview addressing the practical aspects of AIT in clinical practice based on published evidence and the experience of international experts in the field. Topics covered include interpretation and translation of clinical trial data into everyday clinical practice (eg, allergen doses and treatment duration), assessment of risk and treatment of local and systemic allergic reactions, recommendations for improvement of AIT guidelines, and identification of appropriate data for seeking regulatory approval, to name a few. Many informational gaps in AIT practice need further evaluation as products and practices evolve.Entities:
Keywords: Allergic rhinitis; Allergy immunotherapy; Asthma; Clinical practice; Guidelines
Mesh:
Substances:
Year: 2020 PMID: 32422372 DOI: 10.1016/j.jaip.2020.04.071
Source DB: PubMed Journal: J Allergy Clin Immunol Pract